Sign In

Login

Password

Forgot Password ? Sign Up

Adalimumab (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Adalimumab" in Polish language version.

refsWebsite
Global rank Polish rank
24nih.gov
4th place
7th place
8doi.org
2nd place
6th place
2web.archive.org
1st place
1st place
2humira.com
low place
low place
1europa.eu
68th place
31st place
1bmj.com
1,226th place
1,204th place
1archive.is
87th place
5th place
1pulsmedycyny.com.pl
low place
low place

archive.is

bmj.com

gut.bmj.com

doi.org

  • Lovell DJ., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., Nemcova D., Mouy R., Sandborg C., Bohnsack J., et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. „The New England journal of medicine”. 8 (359), s. 810–820, sierpień 2008. DOI: 10.1056/NEJMoa0706290. PMID: 18716298. 
  • J.F. Colombel, W.J. Sandborn, R. Panaccione, A.M. Robinson i inni. Adalimumab safety in global clinical trials of patients with Crohn’s disease. „Inflamm Bowel Dis”. 15 (9), s. 1308–1319, Sep 2009. DOI: 10.1002/ibd.20956. PMID: 19434735. 
  • Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. „J Am Acad Dermatol”. 1 (58), s. 106–115, styczeń 2007. DOI: 10.1016/j.jaad.2007.09.010. PMID: 17936411. 
  • Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A, Bagot M, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). „Br J Dermatol”. 3 (158), s. 558–566, marzec 2008. DOI: 10.1111/j.1365-2133.2007.08315.x. PMID: 18047523. 
  • G.R. D’Haens, R. Panaccione, P.D. Higgins, S. Vermeire i inni. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn’s and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?. „Am J Gastroenterol”, Nov 2010. DOI: 10.1038/ajg.2010.392. PMID: 21045814. 
  • S.B. Hanauer. The role of biologics in ulcerative colitis. „Dig Dis”. 28 (3), s. 497–500, 2010. DOI: 10.1159/000320408. PMID: 20926878. 
  • N. Gies, K.I. Kroeker, K. Wong, R.N. Fedorak. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. „Aliment Pharmacol Ther”. 32 (4), s. 522–528, Aug 2010. DOI: 10.1111/j.1365-2036.2010.04380.x. PMID: 20500733. 
  • W. Afif, J.A. Leighton, S.B. Hanauer, E.V. Loftus i inni. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. „Inflamm Bowel Dis”. 15 (9), s. 1302–1307, Sep 2009. DOI: 10.1002/ibd.20924. PMID: 19408340. 

europa.eu

ema.europa.eu

humira.com

nih.gov

ncbi.nlm.nih.gov

  • Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. „Expert Opin Biol Ther”. 5. 11, s. 1491–1504, 2005. PMID: 16255652. 
  • Fenner H. Immunopharmacologic profile and therapeutic prospects of anti-TNF-alpha therapy. „Z Rheumatol”. 57. 5, s. 294–297, 1998. PMID: 9864833. 
  • Seiderer J, Brand S, Dambacher J, e al. Adalimumab in patients with Crohn’s disease--safety and efficacy in an open-label single centre study. „Aliment Pharmacol Ther”. 25. 7, s. 787–796, 2007. PMID: 17373917. 
  • Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. „Arthritis Rheum”. 48. 1, s. 35–45, 2003. PMID: 12528101. 
  • Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. „Ann Rheum Dis”. 65. 6, s. 753–759, 2006. PMID: 16308341. 
  • Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. „Arthritis Rheum”. 50. 5, s. 1400–1411, 2004. PMID: 15146409. 
  • Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. „Arthritis Rheum”. 54. 1, s. 26–37, 2006. PMID: 16385520. 
  • Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). „J Rheumatol”. 12, s. 2563–2571, 2003. PMID: 14719195. 
  • Lovell DJ., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., Nemcova D., Mouy R., Sandborg C., Bohnsack J., et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. „The New England journal of medicine”. 8 (359), s. 810–820, sierpień 2008. DOI: 10.1056/NEJMoa0706290. PMID: 18716298. 
  • Simpson D, Scott LJ. Adalimumab: in psoriatic arthritis. „Drugs”. 66. 11, s. 1487–1496, 1497–9, 2006. PMID: 16906782. 
  • Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. „J Rheumatol”. 34. 5, s. 1040–1050, 2007. PMID: 17444593. 
  • van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. „Arthritis Rheum”. 54. 7, s. 2136–2146, 2006. PMID: 16802350. 
  • Davis JC Jr, Revicki D, van der Heijde DM, et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. „Arthritis Rheum”. 57. 6, s. 1050–1057, 2007. PMID: 17665483. 
  • W.P. Maksymowych. Update on the treatment of ankylosing spondylitis. „Ther Clin Risk Manag”. 3 (6), s. 1125–1133, Dec 2007. PMID: 18516314. 
  • Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn’s disease. „BioDrugs”. 21. 2, s. 125–132, 2007. PMID: 17402796. 
  • Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. „Gastroenterology”. 130. 2. s. 323–333. PMID: 16472588. 
  • Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. „Gastroenterology”. 132. 1, s. 52–65, 2007. PMID: 17241859. 
  • J.F. Colombel, W.J. Sandborn, R. Panaccione, A.M. Robinson i inni. Adalimumab safety in global clinical trials of patients with Crohn’s disease. „Inflamm Bowel Dis”. 15 (9), s. 1308–1319, Sep 2009. DOI: 10.1002/ibd.20956. PMID: 19434735. 
  • Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. „J Am Acad Dermatol”. 1 (58), s. 106–115, styczeń 2007. DOI: 10.1016/j.jaad.2007.09.010. PMID: 17936411. 
  • Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A, Bagot M, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). „Br J Dermatol”. 3 (158), s. 558–566, marzec 2008. DOI: 10.1111/j.1365-2133.2007.08315.x. PMID: 18047523. 
  • G.R. D’Haens, R. Panaccione, P.D. Higgins, S. Vermeire i inni. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn’s and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?. „Am J Gastroenterol”, Nov 2010. DOI: 10.1038/ajg.2010.392. PMID: 21045814. 
  • S.B. Hanauer. The role of biologics in ulcerative colitis. „Dig Dis”. 28 (3), s. 497–500, 2010. DOI: 10.1159/000320408. PMID: 20926878. 
  • N. Gies, K.I. Kroeker, K. Wong, R.N. Fedorak. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. „Aliment Pharmacol Ther”. 32 (4), s. 522–528, Aug 2010. DOI: 10.1111/j.1365-2036.2010.04380.x. PMID: 20500733. 
  • W. Afif, J.A. Leighton, S.B. Hanauer, E.V. Loftus i inni. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. „Inflamm Bowel Dis”. 15 (9), s. 1302–1307, Sep 2009. DOI: 10.1002/ibd.20924. PMID: 19408340. 

pulsmedycyny.com.pl

web.archive.org